Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary treatment goal is to stimulate hair growth through the alleviation of inflammation at sites of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed for AA; however, tolerability issues, side effects, and the modest efficacy of current treatment options underscore the substantial unmet clinical need in AA. The AA pipeline is active, consisting primarily of targeted immunomodulatory agents, and boasts several marketed and investigational JAK inhibitors (e.g., Eli Lilly’s Olumiant, Incyte’s Jakafi, Concert’s CPT-543) and targeted biologics (e.g., Novartis’s Cosentyx, LEO Pharma’s tralokinumab). This report provides an analysis of AA epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging AA therapies.
- How large is the diagnosed AA population, and how will its size change between 2018 and 2028? How large are the diagnosed alopecia totalis and universalis populations?
- What are the key unmet clinical needs in AA, and to what degree will they be fulfilled by 2028?
- What is the current state of treatment in AA, and how will it evolve over time?
- What emerging AA therapies are viewed by treating dermatologists as most promising, and what sales/uptake will they achieve in AA? How will JAK inhibitors fit into the AA treatment algorithm?
- Geographies: United States and EU5.
- Primary research: six country-specific interviews with thought-leading dermatologists supported by survey data collected for this study.
- Epidemiology: diagnosed and drug-treated prevalence of AA by country.
- Forecast: drug-level sales and patient share of key AA therapies in 2028.
- Emerging therapies:
- Phase II/III: 4 drugs.
- Phase II: 11 drugs.
- Coverage of select preclinical and Phase I products.
- Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.